Centessa prices $250M public offering of 11.6M ADSs at $21.50 per ADS

Centessa Pharmaceuticals plc

Priced 11,627,907 ADSs at $21.50 each; gross proceeds ~$250M; net proceeds ~$234.4M.
Underwriters granted 30-day option to purchase up to 1,744,186 additional ADSs.
Offering expected to close November 14, 2025; proceeds to fund product development and general corporate purposes.
Existing cash plus net proceeds expected to fund operating expenses into 2028.
Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are joint book-running managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.